Alpha-2 agonists — guanfacine (Intuniv) and clonidine (Kapvay) — originated as antihypertensives but have earned a meaningful role in ADHD treatment, particularly in pediatric practice. The mechanism is fundamentally different from stimulants: postsynaptic alpha-2A receptor agonism in the PFC enhances dendritic spine signaling and improves working memory and behavioral inhibition. Different mechanism, converging effect.
- Class
- Alpha-2 adrenergic agonists
- Mechanism
- Postsynaptic alpha-2A agonism in PFC enhances working memory and behavioral inhibition. Also presynaptic alpha-2 effects reduce NE release peripherally (antihypertensive effect).
- Typical dose
- Guanfacine ER 1-7 mg/day; clonidine ER 0.1-0.4 mg/day in divided doses
- Half-life
- Guanfacine ER ~18 hours; clonidine ER ~12 hours
- FDA indications
- ADHD (monotherapy or adjunct to stimulants), hypertension
- Key adverse effects
- Sedation (prominent, especially clonidine), dizziness, dry mouth, hypotension/bradycardia, rebound hypertension if abruptly discontinued
- Representative agents
- Guanfacine ER (Intuniv), clonidine ER (Kapvay), immediate-release forms
Useful adjunct to stimulants for: hyperactivity-impulsivity in addition to attention, tic disorders, sleep difficulties with stimulants, oppositional/aggressive behaviors. Monotherapy: when stimulants/atomoxetine inappropriate. Guanfacine more selective alpha-2A — less sedating than clonidine.
Two clinical roles dominate. As ADHD monotherapy: for patients who can't tolerate stimulants or for whom non-controlled treatment is preferred. The effect size is modest but real. Most commonly used in pediatric ADHD with prominent hyperactivity-impulsivity. As stimulant adjunct: added to a stimulant to extend coverage, manage stimulant-induced sleep difficulties, address residual hyperactivity, or treat comorbid tics. The combination is one of the most common in pediatric ADHD practice.
Specific clinical benefits beyond core ADHD: tics reduction (alpha-2 agonists are evidence-based for Tourette syndrome), oppositional behaviors (clinical signal in oppositional defiant disorder), and sleep difficulties (evening dose can help with stimulant-induced insomnia or with ADHD-associated sleep onset problems).
Alpha-2 agonists treat ADHD through a non-catecholamine-enhancing mechanism — they strengthen prefrontal signaling directly and are especially useful for the hyperactive-impulsive and tic-comorbid presentations.
Mechanism note: Alpha-2 agonists strengthen prefrontal circuits without enhancing catecholamines — useful as monotherapy or stimulant adjunct, and the choice when hyperactivity, emotional dysregulation, or comorbid tics dominate.
Guanfacine is more selective for alpha-2A (PFC-relevant); clonidine has broader alpha-2 activity plus more sedation. Both are available as extended-release formulations (Intuniv, Kapvay) — these are the forms typically used for psychiatric indications.
- Cost
- Guanfacine ER (Intuniv) generic ~$30-80/month. Clonidine ER (Kapvay) generic ~$30-80/month. IR forms ~$5-15/month.
- Generic status
- IR forms generic for decades. Intuniv generic since 2014; Kapvay generic since 2018.
- Formulary typical
- IR Tier 1; ER formulations Tier 1-2.
- Access friction
- Non-controlled — easier than stimulants. Rebound hypertension on abrupt discontinuation is the major patient-education point.
Prescriber tip: For pediatric ADHD with hyperactivity-impulsivity, often combined with stimulant. Counsel taper for discontinuation — patients sometimes stop unilaterally.
Side effects: sedation (more with clonidine, less with guanfacine ER), dizziness, dry mouth, hypotension, bradycardia. The warning point: do not stop alpha-2 agonists abruptly. Rebound hypertension can be significant. Taper over weeks. This is especially important to counsel for patients who tend to discontinue medications unilaterally.
Combined with stimulants, monitor cardiovascular effects of both. Most pediatric ADHD on combination regimens does well, but tracking BP and HR matters.